If you have not already registered for Full Text Access to The Journal, then visit our registration page.


VOLUME 66   2005   NUMBER 10

Original Articles

1205 Prevalence, Correlates, and Comorbidity of Bipolar I Disorder and Axis I and II Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Bridget F. Grant, Frederick S. Stinson, Deborah S. Hasin, Deborah A. Dawson, S. Patricia Chou, W. June Ruan, and Boji Huang
[Abstract] [PDF]

1216 Aripiprazole Augmentation of Antidepressants for the Treatment of Partially Responding and Nonresponding Patients With Major Depressive Disorder. Jeffrey S. Simon and Charles B. Nemeroff
[Abstract] [PDF]

1221 Prevalence and Features of Intermittent Explosive Disorder in a Clinical Setting. [CME] Emil F. Coccaro, Michael A. Posternak, and Mark Zimmerman
[Abstract] [PDF]

1228 Paroxetine Response and Tolerability Among Ethnic Minority Patients With Mood or Anxiety Disorders: A Pooled Analysis. Peter P. Roy-Byrne, Philip Perera, Cornelius D. Pitts, and Jacquie A. Christi
[Abstract] [PDF]

1234 Augmentation With Open-Label Atomoxetine for Partial or Nonresponse to Antidepressants. Linda L. Carpenter, Nada Milosavljevic, Jordan M. Schecter, Audrey R. Tyrka, and Lawrence H. Price
[Abstract] [PDF]

1239 Diagnostic Stability 18 Months After Treatment Initiation for First-Episode Psychosis. Benno G. Schimmelmann, Philippe Conus, Jane Edwards, Patrick D. McGorry, and Martin Lambert
[Abstract] [PDF]

1247 Dissociative Disorders Among Inpatients With Drug or Alcohol Dependency. Figen Karadag, Vedat Sar, Defne Tamar-Gurol, Cuneyt Evren, Mustafa Karagoz, and Murat Erkiran
[Abstract] [PDF]

1254 Sleep and Depression. [CME] Norifumi Tsuno, Alain Besset, and Karen Ritchie
[Abstract] [PDF]

1270 A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder. Stuart A. Montgomery, Rico Nil, Natalie Drr-Pal, Henrik Loft, and Jean-Philippe Boulenger
[Abstract] [PDF]

1279 Associations of Anxiety-Related Symptoms With Reported History of Childhood Sexual Abuse in Schizophrenia Spectrum Disorders. Paul H. Lysaker, Louanne W. Davis, Michael J. Gatton, and Steven M. Herman
[Abstract] [PDF]

1285 Reduction of Opioid-Withdrawal Symptoms With Quetiapine. Harold B. Pinkofsky, Ann M. Hahn, Frances A. Campbell, John Rueda, Dennis C. Daley, and Antoine B. Douaihy
[Abstract] [PDF]

1289 Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance. Richard C. Shelton, Douglas J. Williamson, Sara A. Corya, Todd M. Sanger, Luann E. Van Campen, Michael Case, Susan D. Briggs, and Gary D. Tollefson
[Abstract] [PDF]

1298 Open-Label Study of Atypical Neuroleptic Quetiapine for Treatment of Borderline Personality Disorder: Impulsivity as Main Target. Evens Villeneuve and Sophie Lemelin
[Abstract] [PDF]

1304 Predictors of Everyday Functioning Among Older Mexican Americans vs. Anglo-Americans With Schizophrenia. Neelum D. Jeste, David J. Moore, Sherrill R. Goldman, Jesus Bucardo, Wendy Davila-Fraga, Shahrokh Golshan, Dilip V. Jeste, and Thomas L. Patterson
[Abstract] [PDF]

1312 Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. Aytekin Sir, Russell F. D'Souza, Sukru Uguz, Tom George, Simavi Vahip, Malcolm Hopwood, Andrew J. Martin, William Lam, and Tal Burt
[Abstract] [PDF]

1321 Adjunctive Risperidone in Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study. Olga Brawman-Mintzer, Rebecca G. Knapp, and Paul J. Nietert
[Abstract] [PDF]

1326 Aripiprazole Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment-Resistant Major Depressive Disorder. George I. Papakostas, Timothy J. Petersen, Gustavo Kinrys, Alana M. Burns, John J. Worthington III, Jonathan E. Alpert, Maurizio Fava, and Andrew A. Nierenberg
[Abstract] [PDF]

ASCP Corner

1331 Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents: A Different Story? Christoph U. Correll
[PDF]

Letters To the Editor

1333 Addition of Lamotrigine to Clozapine in Inpatients With Chronic Psychosis. Adolph H. Heck, Izak W. de Groot, and Peter N. van Harten
[PDF]

1333 Is There a Real Difference Between the First Onset of Efficacy for Atypical Antipsychotic Monotherapies in Acute Bipolar Mania? Tamas Treuer and Bruce R. Basson
[PDF]

  • Reply by Paul E. Keck, Jr.

1334 Thyroid Dysfunction During Treatment With Atypical Antipsychotics. Andrew Greenspan, Georges Gharabawi, and Joseph Kwentus
[PDF]

1335 Weight Gain, Sexual Dysfunction, and Bupropion. Michael J. Menaster
[PDF]

  • Reply by Mark Zimmerman, Michael A. Posternak, Naureen Attiullah, Michael Friedman, Robert J. Boland, Scott Baymiller, Stacie Lauro Berlowitz, Shahzad Rahman, Kirsten K. Uy, Steve Singer, Iwona Chelminski, and Tavi Thongy

1339 Treatment-Emergent Psychosis With Aripiprazole. Matthew E. Barnas, Najeeb Hussain, and Georgios Petrides
[PDF]

Book Reviews 1340